HT942525P0045 Notice of Intent to Sole Source HT942525P0045
Summary
AI-generated · Dec 18, 2025Aptagen, LLC will perform DNA aptamer library generation for USAMRIID as a sole-source modification to the existing contract. Deliver between 1 and 4 aptamer library generations per year, with each library containing roughly 1,000–10,000 targeted aptamers aimed at pseudoviruses and/or alpha-conotoxins and/or palytoxins, capable of broad-spectrum interactions across 4–6 viral targets. Work will be conducted in Frederick, Maryland, and the Performance Work Statement remains the same except for the increased number of generations and the addition of pseudoviruses as a target.
This effort supports USAMRIID project CB11484, Development of broad-spectrum DNA aptamers to neutralize toxins, enabling researchers to generate aptamers that can effectively bind and neutralize specific toxins and viruses. The approach is embryonic and has not been used at the institute previously. The action is a sole-source modification under FAR Part 6.
The Defense Health Agency Contracting Activity (DHACA) intends to modify the existing contract for an increase in service on a sole source basis In Accordance With (IAW) Federal Acquisition Regulation (FAR) part 6 to Aptagen, LLC located at 250 N Main Street, Jacobus, PA 17407 as the only responsible source that can provide the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) for services. The Performance Work Statement has not changed other than to adjust the number of DNA aptamer generations being provided and adding an additional target of pseudoviruses. USAMRIID has a need to generate no less than one (1) but not to exceed four (4) DNA Aptamer Library Generation per year. These aptamer libraries will consist of ~1000 - ~10,000 targeted aptamers. These libraries target specific pseudoviruses and/or alpha-conotoxins and/or palytoxins and should be capable of broad-spectrum interactions and libraries targeting four (4) to six (6) viral targets. This is a requirement that was originally identified to support USAMRIID s project CB11484, Development of broad-spectrum DNA aptamers to neutralize toxins. The requirement is crucial as it enables USAMRIID s researchers to ultimately generate one (1) or more DNA aptamers capable of effectively binding and neutralizing specific toxins and viruses. This is an embryonic methodology with promising outlook for future use in the research field as this and similar strategies have not been employed at the institute previously. The services will performed in Frederick , Maryland 21702.
From Special Notice posted on Dec 17, 2025Notice history
1-
Special Notice LATEST Posted Dec 17, 2025
Details
Award Information
Not yet awarded
Contacts
Agency
Place of Performance
USA